Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.

Christian Buske,Alessandra Tedeschi,Judith Trotman,Ramón García-Sanz,David MacDonald,Véronique Leblond,Beatrice Mahe,Charles Herbaux,Jeffrey Matous,Constantine S. Tam,Leonard T. Heffner,Marzia Varettoni,M. Lia Palomba,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jerry Ping,B. Hauns,Israel Arango-Hisijara,Meletios A. Dimopoulos

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.

2021

PURPOSEThe double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenstrom's macroglobulinemia (WM). Here, we present the final...

Keywords:

Macroglobulinemia
Placebo
Rituximab
Oncology
Ibrutinib
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations